Posts tagged IPO
HCW starts Gemphire at buy

H.C. Wainwright launched coverage of Gemphire Therapeutics (NASDAQ:GEMP) with a “buy” rating and a price target of $21, saying it views the sell off in the shares following results of the ROYAL-1 clinical trial as overdone. The stock closed at $9.17 on August 30.

Read More
Analysts start Tactile Systems at buy, outperform

Analysts at BTIG Research, Piper Jaffray and William Blair initiated coverage of Tactile Systems Technology (NASDAQ:TCMD) with “buy,” “overweight” and “outperform” ratings, respectively.

Tactile makes pneumatic compression devices (PCD) to treat lymphedema, along with a chronic venous leg ulcer product. Tactile closed an IPO of 4,120,000 shares at $10 apiece earlier this month. The stock was changing hands at $12.98 at mid-day Monday.

Read More
Leerink upgrades Intellia Therapeutics to outperform

Leerink Partners upgraded Intellia Therapeutics (NASDAQ:NTLA) to “outperform” from “market perform” on valuation, with a price target of $32. The stock closed at $17.66 on Thursday.

“We believe the current valuation, close to the mid-point of the IPO range of $16-$18, represents an attractive entry point to own one of the most exciting technology platforms biotech has to offer,” writes analyst Michael Schmidt.

Read More
Cellect completes NASDAQ IPO

Cellect Biotechnology (NASDAQ:APOP; TASE:CLBD) priced an initial public offering in the U.S. of 1,292,308 American Depository Shares (ADSs) and warrants to purchase up to 969,231 ADSs.

Read More
Maxim cuts Galmed Pharma price target to $9

Maxim Group lowered its price target for Galmed Pharmaceuticals (NASDAQ:GLMD) to $9 from $24, citing a bearish biotech market environment, catalysts, and revisions to timelines, as well as other related assumptions. The stock was changing hands at $4.26 in Monday afternoon trading.

Analyst Jason Kolbert writes that the next major inflection point for Galmed is proof-of-concept data for Aramchol in nonalcoholic steatohepatitis (NASH) in 2018.

Read More
Piper resumes coverage of NxStage Medical at overweight

Piper Jaffray has resumed coverage of NxStage Medical (NASDAQ:NXTM) with an “overweight” rating and $18.50 price target, down from $23 previously. The stock closed at $14.96 on Wednesday.

“We have known the story since its late 2005 IPO and watched the evolution of the business from one focused on hospital and home hemodialysis (HHD) to one that can provide virtually all the supplies clinicians and patients need to treat end-stage renal failure,” writes analyst Matt O’Brien.

Read More
Marc Becker joins CRISPR Therapeutics as CFO

Closely-held CRISPR Therapeutics has appointed Marc Becker as CFO to further support the company’s efforts to develop game-changing drugs derived from its proprietary CRISPR-Cas9 gene-editing technology platform.

Mr. Becker is a seasoned executive who brings more than 20 years of experience in commercial, operational and corporate finance and a deep understanding of the global biopharmaceutical industry.

Read More